Safe and Effective T Cell-Driven Therapies For Solid Tumors: A Dream Within Reach
The industry has witnessed a lot of progress with cell therapies for blood cancers. The next critically important goal must be to find a safe and effective pathway for cell therapies in patients with solid tumors.
You may also be interested in...
Gilead ups its investment in its TIGIT partner, as the firms pivot to a less crowded market opportunity in upper GI cancers.
While an EU-level project is underway to address delays to drug trials that are conducted in combination with IVD performance studies, Denmark has streamlined its processes to address the issue at the national level.
Twelve new drugs are now being reviewed for potential EU marketing approval, including Servier’s vorasidenib for IDH-mutant diffuse glioma, which the company says could become the first targeted therapy for the malignant and incurable brain tumor.